Pharmacotherapy for tonic–clonic seizures

@article{Rheims2014PharmacotherapyFT,
  title={Pharmacotherapy for tonic–clonic seizures},
  author={Sylvain Rheims and Philippe Ryvlin},
  journal={Expert Opinion on Pharmacotherapy},
  year={2014},
  volume={15},
  pages={1417 - 1426}
}
Introduction: Occurrence of generalized tonic–clonic seizures (GTCS) is one of the most important risk factors of seizure-related complications and comorbidities in patients with epilepsy. Their prevention is therefore an important aspect of therapeutic management both in idiopathic generalized epilepsies and in focal epilepsies. Areas covered: It has been shown that the efficacy of antiepileptic drugs (AEDs) varies across epilepsy syndromes, with some AEDs efficacious against focal seizures… Expand
Perampanel: Another Choice for Patients with Idiopathic Generalized Epilepsy who Have Tonic–Clonic Seizures
  • A. Pack
  • Medicine
  • Epilepsy currents
  • 2016
TLDR
Perampanel as adjunctive therapy for treatment of drug resistant primary generalized tonic–clonic seizures in adults and adolescents with refractory idiopathic generalized epilepsy was investigated in a multicenter, international, double-blind, placebo-controlled, parallel-group study. Expand
Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy
TLDR
A placebo-controlled clinical phase III study including 164 patients in idiopathic generalized epilepsies (IGE) demonstrated efficacy of PER in reducing pGTCS with good tolerability profile, and without aggravating absence seizures or myoclonic seizures. Expand
[Current possibilities of treatment of generalized convulsive seizures].
TLDR
Current possibilities of treatment of generalized convulsive seizures are presented and Perampanel, an agonist of AMPA-receptors, is a new drug approved in more than 40 countries, including Russia. Expand
Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy
TLDR
This study provides Class I evidence that adjunctive perampanel reduces PGTC seizure frequency, compared with placebo, in patients with drug-resistant PGTC seizures in IGE. Expand
Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies
TLDR
Considering the effect of DRE on psychologic status and social integration, comprehensive care adaptations are always needed in order to improve patients’ quality of life. Expand
Prevention of generalized tonic–clonic seizures in refractory focal epilepsy: A meta‐analysis
TLDR
Whether some antiepileptic drugs (AEDs) might be more efficacious than others on SGTCS in patients with drug‐resistant focal epilepsy thus represents an important clinical issue for which no data are currently available. Expand
The challenges of treating epilepsy with 25 antiepileptic drugs.
TLDR
This review will focus on the strategies to treat epilepsy by choosing among 25 available drugs, including drugs with different mechanisms of action, pharmacokinetics, efficacy and tolerability. Expand
Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension
TLDR
Adjunctive lacosamide did not systematically worsen absence or myoclonic seizures, and appears to be well tolerated in patients with PGE. Expand
Perampanel: A Review in Drug-Resistant Epilepsy
TLDR
Clinical experience with perampanel is accumulating, although comparative studies and pharmacoeconomic data that could assist in positioning it relative to other AEDS that are approved and/or recommended as adjunctive therapy are lacking. Expand
Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study
TLDR
A post-hoc analysis of data from three Phase III studies of adults with focal seizures taking 1-2 AEDs who received placebo or BRV 50-200mg/day without titration indicates that previous treatment failure with LEV does not preclude the use of BRV in patients with epilepsy. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 97 REFERENCES
Evidence‐based Treatment of Idiopathic Generalized Epilepsies with New Antiepileptic Drugs
TLDR
It is postulated that lamotrigine (LTG), levetiracetam (LEV), topiramate (TPM), and zonisamide (ZSM) may have efficacy for a broad spectrum of seizure types including those of IGE. Expand
Lamotrigine add-on for drug-resistant partial epilepsy.
TLDR
Lamotrigine add-on therapy is effective in reducing the seizure frequency, in patients with drug-resistant partial epilepsy, though there may be minor benefits in affect balance (happiness) and mastery. Expand
Tiagabine-induced absence status in idiopathic generalized epilepsy
TLDR
A 32-year-old patient with absence epilepsy and primary generalized tonic-clonic seizures since 11 years of age, who developed her first absence status epilepticus while treated with TGB daily is described. Expand
Zonisamide in the management of epilepsy—Japanese experience
TLDR
Zonisamide represents a valuable broad-spectrum option for the treatment of epilepsy and is well-tolerated with a low incidence of adverse events, which are generally mild and CNS-related. Expand
Depression in epilepsy: a critical review from a clinical perspective
TLDR
Antidepressant drugs and psychotherapy have shown moderate efficacy in the treatment of depression comorbidity, but randomized controlled trials in patients with epilepsy are lacking, especially for drugs. Expand
Prevention of sudden unexpected death in epilepsy: A realistic goal?
TLDR
Developing effective prevention ofudden unexpected death in epilepsy will depend on better understanding of the pathophysiology of SUDEP to define the most appropriate targets of intervention, and identification of risk factors for SUDEP that would allow for the design of feasible clinical trials to test targeted interventions in high‐risk populations. Expand
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures
TLDR
It is suggested that levetiracetam is an effective and well-tolerated adjunctive treatment for patients with previously uncontrolled idiopathic generalized epilepsy with myoclonic seizures. Expand
The pharmacological treatment of epilepsy in adults
TLDR
Antiepileptic drug choice is primarily based on evidence of efficacy and effectiveness for the individual's seizure type, but other patient-specific factors need to be considered, including age, sex, childbearing potential, comorbidities, and concomitant medications. Expand
Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures.
BACKGROUND This is an updated version of the previously published Cochrane review (Issue 4, 2009)Worldwide, phenytoin and valproate are commonly used antiepileptic drugs. It is generally believedExpand
Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy
TLDR
Adjunctive levetiracetam is an effective and well-tolerated antiepileptic drug for treating generalized tonic-clonic seizures in patients with idiopathic generalized epilepsies. Expand
...
1
2
3
4
5
...